BioSpace News Archive

Small Pharma Inc. is pleased to announce its attendance at the LSX Inv€$tival Showcase TM conference and the Jefferies London Healthcare Conference during the month of November.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), today reported financial results for the quarter ended September 30, 2021.

Motus GI Holdings, Inc., a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, reported its financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.

From 2019 to 2029, the global spinal fusion market would grow at a moderate pace. This would translate to a plethora of novel opportunities.

American CryoStem Corporation, a leading strategic cellular application developer, global licensor of patented adipose tissue-based technologies for the Regenerative and Personalized Medicine industries, announced an agreement has been reached between the Company and ACS Global, Inc to exchange 20,000,000 million CRYO common shares currently held by ACS Global, Inc for 1,000,000 shares of preferred stock.

Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics provides an update regarding the Company’s Third Quarter Results and recent corporate developments.

Oncopeptides AB . According to the principles for the appointment of the Nomination Committee in Oncopeptides AB, the Nomination Committee for the annual general meeting 2022 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30, along with the Chairman of the Board of Directors.

Nordic Nanovector ASA announces that it will report its results for the third quarter 2021 on Thursday, 18 November 2021.

Athersys reports that HEALIOS K.K., its development and commercial partner in Japan, provided an update earlier this morning regarding its clinical programs for acute respiratory distress syndrome and ischemic stroke involving MultiStem® in its FY2021 Q3 financial results presentation.

Johnson & Johnson announced its intent to separate the Company’s Consumer Health business, creating a new publicly traded company.